Technology ID

Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases

Lead Inventor
Siegel, Richard (NIAMS)
Meylan, Francoise (NIAMS)
Song, Yun-Jeong (NIAMS)
Research Materials
Therapeutic Areas
Development Status
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
Lead IC
Autoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies such as TNF-alpha antagonists have been developed.

In experiments with mice, NIAMS inventors have shown that the interaction between the TNF family ligand TL1A with its receptor, DR3, is critical for development of disease in asthma, inflammatory bowel disease and multiple sclerosis. They have also developed anti-TL1A antibodies that prevent disease in mouse models of rheumatoid arthritis and inflammatory bowel disease.

This technology describes anti-mouse TL1A and anti-human TL1A monoclonal antibodies that may be useful for the development of diagnostics and therapeutics for autoimmune inflammatory disease, as well as methods of treating such disease by blocking the interaction between TL1A and DR3.
Commercial Applications
  • Antibody-based therapeutics for autoimmune inflammatory disease
  • Diagnostics for autoimmune inflammatory disease
  • Research tools to probe the role of TL1A-DR3 interactions in the development of autoimmune disease
Competitive Advantages
  • Specific immunomodulatory effect provides potential for potent therapy without inducing global immunosuppression
  • Anti-TL1A monoclonal antibodies available for further development
Licensing Contact:
Crooks, Denise
Phone: 301-435-0103